Levetiracetam +pharma

Levetiracetam, the active ingredient in Levetiracetam +pharma, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset, generalized tonic‑clonic, and myoclonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide through reliable logistics.

Levetiracetam is an antiepileptic drug used to control several seizure types.

Partial‑onset seizures: reduces seizure frequency and severity in patients with focal epilepsy. Generalized tonic‑clonic seizures: helps control convulsive episodes in generalized epilepsy. Myoclonic seizures: decreases myoclonic jerks in appropriate seizure syndromes.

Levetiracetam may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior - Blood dyscrasias such as neutropenia - Severe depression or mood changes - Multi‑organ hypersensitivity reactions - Respiratory depression in rare cases

When prescribing levetiracetam, consider the following precautions. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic disease: monitor liver function, although metabolism is minimal. - Mood changes: observe for depression, anxiety, or suicidal ideation. - Discontinuation: avoid abrupt cessation to prevent seizure exacerbation. - Pregnancy: safety category unknown; weigh benefits against potential risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Levetiracetam can interact with other medicines; monitor patients accordingly.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, reducing levetiracetam levels. - Phenytoin: enzyme induction may lower drug exposure. - Rifampin: strong inducer that decreases plasma concentrations.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam concentrations. - Oral contraceptives: potential reduction in hormonal efficacy. - Alcohol: additive CNS depression, requiring caution.